iPSC Reprogramming Patents: Who Leads, Where the Gaps Are 2026
Induced pluripotent cell reprogramming patents: who holds the reprogramming factor claims, and where filing has slowed
23.2% concentration at the top. The five leading assignees hold 895 of 3,859 records in scope, but the tenth-ranked entrant still files at 95 — a genuine long tail, not a two-player field. Filings rose from 196 in 2017 to a peak of 299 in 2022, then fell to 123 by 2024 — a 43% drop over the 2021-2024 span. Treat 2025 and 2026 counts as still filling in rather than as continued decline.
- 1FACTOR BIOSCIENCE INC5.6%
- 2WHITEHEAD INST FOR BIOMEDICAL RES4.8%
- 3THE SCRIPPS RES INST4.7%
- 4CHILDRENS MEDICAL CENT CORP4.6%
- 5RGT UNIV OF CALIFORNIA3.5%
See the full induced pluripotent cell reprogramming analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on iPSC reprogramming patents
Who holds the most patents on induced pluripotent cell reprogramming?
The ranking covers 100 assignees drawn from 3,859 patent families in scope, with a single leader holding 217 records. That leader is followed by a steep initial drop-off to 134 records at fifth place and 95 at tenth, then a long tail of smaller filers. No single company controls the field outright; the top five combined hold only 23.2% of all records, so a competitive review needs to look well beyond the top names.
Is patent filing in cellular reprogramming slowing down?
Filings peaked at 299 records in 2022 and fell to 123 by 2024, a documented 43% decline over that three-year span. That is the most recent stretch the data can treat as a complete trend. The 2025 and 2026 figures are much lower still, but that reflects the roughly 18-month lag between filing and publication rather than a further collapse in activity, so they should not be read as continued decline.
What technologies dominate iPSC reprogramming patent claims?
C12N, the genetic engineering and microorganism class, appears on 88.9% of the 3,859 records in scope, making it the structural core of nearly every filing. A61K medicinal-preparation claims follow at 40.0%, showing that a large share of filers extend a reprogramming method into a therapeutic application claim. Smaller classes like G01N testing (7.9%) and C12M bioreactor apparatus (3.5%) cover more specific process and equipment claims and carry much lower filing density.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Induced Pluripotent Cell Reprogramming covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.